CMV Clinical Trial - Clinical Evaluation of the QuantiFERON CMV Assay

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT04101136` - Effect of Atorvastatin on Subclinical Atherosclerosis	N/A
Recruiting	`NCT06001320` - De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Trans Recip	Early Phase 1
Completed	`NCT01923766` - Cytotoxic T Cells to Prevent Virus Infections	Phase 1
Not yet recruiting	`NCT05969743` - Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease	Phase 2
Recruiting	`NCT01011712` - The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
Recruiting	`NCT06034925` - Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients	Phase 4
Completed	`NCT04840199` - A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.	Phase 2
Not yet recruiting	`NCT06211543` - Letermovir (LMV) Prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients With CMV Seropositive Donors: an Exploratory Study From Spanish GETH/TC Centers
Recruiting	`NCT04056533` - Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy	Phase 2
Not yet recruiting	`NCT04280380` - Cytomegalovirus Infection in Critically Ill Patients and Patients Receiving Anticancer Therapy
Active, not recruiting	`NCT03924219` - CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
Completed	`NCT02694484` - Search Cytomegalovirus in Healthy Volunteers Stools Samples Selected as Potential Donor for Fecal Microbiota Transplant	N/A
Recruiting	`NCT06011486` - Expansion of Virus-Specific Lymphocytes for Cell Therapy	Phase 1
Recruiting	`NCT04017962` - A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection	Phase 2
Terminated	`NCT03570411` - Evaluating the Clinical Utility of the T-SPOT.CMV Assay for the Prediction of CMV Reactivation Among Pediatric Patients Undergoing Hematopoietic Cell Transplant
Enrolling by invitation	`NCT04392297` - Clinical and Immunological Features of the CMV Infection Atypical Course in Immunocompetent Individuals
Completed	`NCT00872703` - Does Normal Brain Imaging Predict Normal Neurodevelopmental Outcome in Fetuses With Proven Cytomegalovirus Infection?	N/A
Active, not recruiting	`NCT01945814` - Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)	Phase 1
Recruiting	`NCT05041426` - Letermovir for CMV Prevention After Lung Transplantation	Phase 2
Recruiting	`NCT03858907` - Cytomegalovirus Risk in Seropositive Kidney Transplant Recipients Stratified by Quantiferon-CMV

NCT number	NCT03502161
Study type	Observational
Source	QIAGEN Gaithersburg, Inc
Contact
Status	Terminated
Phase
Start date	November 15, 2018
Completion date	June 30, 2020

Clinical Evaluation of the QuantiFERON CMV Assay

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms